logo

For the Inventor, By the Inventor

San Diego, CA, United States of America

Takeda San Diego, Inc.

Calculating rank
USPTO Granted Patents = 53

% Expired Patents = 94.3



Forward Citations = 230

Loading Chart...
Loading Chart...

82 inventors (with patents filed for the assignee):

goldMedal Jeffrey Alan Stafford (12 out of 143 patents)

silverMedal Stephen L Gwaltney (10 out of 35 patents)

bronzeMedal Jerome C Bressi (9 out of 12 patents)

4.  Douglas R Dougan (9 out of 9 patents)

5.  Jun Feng (8 out of 85 patents)

6.  Sheldon Cao (8 out of 20 patents)

7.  Robert J Skene (8 out of 9 patents)

8.  Laurent Martin (8 out of 12 patents)

9.  John W Palan (8 out of 8 patents)

10.  Phong H Vu (7 out of 14 patents)

11.  Anthony R Gangloff (7 out of 19 patents)

12.  Andrew John Jennings (7 out of 14 patents)

13.  David J Hosfield (7 out of 9 patents)

14.  Clifford D Mol (7 out of 9 patents)

15.  Ciaran N Cronin (7 out of 7 patents)


Core Competencies:
Glucokinase Activators
Histone Deacetylase Inhibitors
Dipeptidyl Peptidase Inhibitors
Crystallization Techniques
Pyrazole Compounds
Imidazopyridine Compounds
Hydroxysteroid Dehydrogenase Inhibitors
MAPK/ERK Kinase
Protein Kinase B
Microfluidic Devices
Crystalline Composition
Assay Kits

53 patents:

1. 8563730 - Pyrazole and fused pyrazole glucokinase activators (2013-10-22),
2. 8530499 - Glucokinase activators (2013-09-10),
3. 8173645 - Glucokinase activators (2012-05-08),
4. 8163779 - Glucokinase activators (2012-04-24),
5. 8124617 - Imidazopyridine compounds (2012-02-28),
6. 8034822 - Glucokinase activators (2011-10-11),
7. 8008332 - Substituted indazoles as glucokinase activators (2011-08-30),
8. 7759339 - Hydroxysteroid dehydrogenase inhibitors (2010-07-20),
9. 7741494 - Histone deacetylase inhibitors (2010-06-22),
10. 7732475 - Histone deacetylase inhibitors (2010-06-08),
11. 7723344 - Dipeptidyl peptidase inhibitors (2010-05-25),
12. 7696218 - Substituted 1,3-dialkyl-2,4-dioxo-6-(arylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acid inhibitors of MAPK/ERK kinase (2010-04-13),
13. 7687638 - Dipeptidyl peptidase inhibitors (2010-03-30),
14. 7642275 - Histone deacetylase inhibitors (2010-01-05),
15. 7642253 - Histone deacetylase inhibitors (2010-01-05),
Company Overview
Takeda San Diego, Inc. is a biotechnology company based in San Diego, California, specializing in the development of innovative therapies. The organization focuses on glucokinase activators and has a diverse portfolio that includes histone deacetylase inhibitors, dipeptidyl peptidase inhibitors, and various compound classes such as pyrazole and imidazopyridine compounds. Takeda's research is dedicated to advancing treatments that target metabolic and other complex diseases, leveraging advanced crystallization techniques and insights into hydroxysteroid dehydrogenase and MAPK/ERK kinase pathways.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

Takeda San Diego, Inc. USPTO Patent Assignee Logo
53 Patents

#117 in San Diego, CA

#1,566 in California

#6,672 in US

#13,348 in the World

San Diego, CA (US)
San Diego, CA, United States of America

Takeda San Diego, Inc.

Forward Citations = 230

82 inventors:

goldMedal Jeffrey Alan Stafford (12 out of 143 patents)

silverMedal Stephen L Gwaltney (10 out of 35 patents)

bronzeMedal Jerome C Bressi (9 out of 12 patents)

4.  Douglas R Dougan (9 out of 9 patents)

5.  Jun Feng (8 out of 85 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Takeda San Diego, Inc.. Retrieved from https://idiyas.com/company/takeda-san-diego

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…